Zyclara

Zyclara is a brand name of imiquimod topical, approved by the FDA in the following formulation(s):

ZYCLARA (imiquimod - cream; topical)

• 
  Manufacturer: MEDICIS
  
  Approval date: March 25, 2010
  
  Strength(s): 3.75% ^[RLD]


• 
  Manufacturer: MEDICIS
  
  Approval date: July 15, 2011
  
  Strength(s): 2.5% ^[RLD]

Has a generic version of Zyclara been approved?

No. There is currently no therapeutically equivalent version of Zyclara available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zyclara. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Zyclara.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 25, 2013 - NEW PRODUCT
  
  
  • March 24, 2014 - TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
  
  
  • July 15, 2014 - NEW STRENGTH
  
  

See also...

• Zyclara Consumer Information (Drugs.com)
• Zyclara Cream Consumer Information (Wolters Kluwer)
• Zyclara Consumer Information (Cerner Multum)
• Zyclara Topical Advanced Consumer Information (Micromedex)
• Imiquimod Consumer Information (Wolters Kluwer)
• Imiquimod Cream Consumer Information (Wolters Kluwer)
• Imiquimod topical Consumer Information (Cerner Multum)
• Imiquimod Topical Advanced Consumer Information (Micromedex)
• Imiquimod AHFS DI Monographs (ASHP)